New EU Wastewater Rules Put Pharmaceutical Micropollutant Monitoring in the Spotlight | LCGC InternationalNew EU Wastewater Rules Put Pharmaceut...
Published by Water Network Research, Official research team of The Water Network

New EU Wastewater Rules Put Pharmaceutical Micropollutant Monitoring in the Spotlight | LCGC International
New EU Wastewater Rules Put Pharmaceutical Micropollutant Monitoring in the Spotlight
Author(s)John Chasse
Directive (EU) 2024/3019 makes drug manufacturers financially responsible for removing pharmaceutical residues from wastewater and introduces stricter, standardized monitoring requirements that are set to increase demand for trace-level analytical expertise.
Europe’s pharmaceutical industry is preparing for a major shift in how it accounts for drug residues in the environment according to a recent blog entry on the Veolia (a French multinational company that provides water, waste, and energy management services to help municipalities and industries conserve and replenish resources) website , and analytical laboratories are likely to feel the effects. Directive (EU) 2024/3019 redraws environmental sustainability priorities for the sector, introducing stricter monitoring requirements, a new tier of wastewater treatment, and a principle that makes drug manufacturers financially responsible for removing the micropollutants their products leave behind.
Producers Pay for Removal
At the heart of the directive is extended producer responsibility (EPR). Under this approach, pharmaceutical companies must take part in a centralized organization that collectively manages their EPR obligations. Through it, they will help fund investment in advanced wastewater treatment, along with the systems used to monitor micropollutants and to collect and verify the resulting data. The change marks a significant departure from earlier practice, shifting the burden of dealing with pharmaceutical residues toward the companies that produce them.
Wastewater Quality Testing Procedures. © Mahmuda - stock.adobe.com
Wastewater Quality Testing Procedures. © Mahmuda - stock.adobe.com
Tougher Monitoring and Standardized Methods
For analytical scientists, the most relevant provisions concern monitoring. The directive calls for measuring the concentrations of specific pharmaceutical substances in wastewater and assessing how effectively treatment processes remove them. To make results transparent and comparable across facilities and member states, companies will need to adopt standardized analytical methods.
That requirement is likely to increase demand for robust, validated methods capable of quantifying drug residues at trace levels in complex wastewater matrices, along with harmonized procedures for sampling, quality control, and data reporting. Measuring removal efficiency also means analyzing samples both before and after treatment, which will place a premium on accuracy and reproducibility at low concentrations.
Quaternary Treatment on the Horizon
The directive also introduces quaternary treatment, an additional stage beyond conventional processes designed specifically to remove micropollutants. Plants using it will need to remove 80% of at least six target substances. Large treatment plants will begin implementing it from 2033, with requirements extending progressively through 2045. The phased schedule is intended to give operators and manufacturers time to plan and install the necessary technology without disrupting operations.
New EU Wastewater Rules Put Pharmaceutical Micropollutant Monitoring in the Spotlight
Author(s)John Chasse
Directive (EU) 2024/3019 makes drug manufacturers financially responsible for removing pharmaceutical residues from wastewater and introduces stricter, standardized monitoring requirements that are set to increase demand for trace-level analytical expertise.
Europe’s pharmaceutical industry is preparing for a major shift in how it accounts for drug residues in the environment according to a recent blog entry on the Veolia (a French multinational company that provides water, waste, and energy management services to help municipalities and industries conserve and replenish resources) website , and analytical laboratories are likely to feel the effects. Directive (EU) 2024/3019 redraws environmental sustainability priorities for the sector, introducing stricter monitoring requirements, a new tier of wastewater treatment, and a principle that makes drug manufacturers financially responsible for removing the micropollutants their products leave behind.
Producers Pay for Removal
At the heart of the directive is extended producer responsibility (EPR). Under this approach, pharmaceutical companies must take part in a centralized organization that collectively manages their EPR obligations. Through it, they will help fund investment in advanced wastewater treatment, along with the systems used to monitor micropollutants and to collect and verify the resulting data. The change marks a significant departure from earlier practice, shifting the burden of dealing with pharmaceutical residues toward the companies that produce them.
Wastewater Quality Testing Procedures. © Mahmuda - stock.adobe.com
Wastewater Quality Testing Procedures. © Mahmuda - stock.adobe.com
Tougher Monitoring and Standardized Methods
For analytical scientists, the most relevant provisions concern monitoring. The directive calls for measuring the concentrations of specific pharmaceutical substances in wastewater and assessing how effectively treatment processes remove them. To make results transparent and comparable across facilities and member states, companies will need to adopt standardized analytical methods.
That requirement is likely to increase demand for robust, validated methods capable of quantifying drug residues at trace levels in complex wastewater matrices, along with harmonized procedures for sampling, quality control, and data reporting. Measuring removal efficiency also means analyzing samples both before and after treatment, which will place a premium on accuracy and reproducibility at low concentrations.
Quaternary Treatment on the Horizon
The directive also introduces quaternary treatment, an additional stage beyond conventional processes designed specifically to remove micropollutants. Plants using it will need to remove 80% of at least six target substances. Large treatment plants will begin implementing it from 2033, with requirements extending progressively through 2045. The phased schedule is intended to give operators and manufacturers time to plan and install the necessary technology without disrupting operations.
Tags
- Pharmaceuticals Waste
- Industrial Wastewater Treatment
- Monitors
- Wastewater Collection
- Water and Wastewater
- Condition Monitoring